Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259074 | 0.89 | DGAT2 (0.41) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239216 | 0.88 | DGAT2 (0.50) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239222 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239173 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239151 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20259121 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239337 | 0.85 | DGAT2 (0.58) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20239338 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL20259158 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1ALDH1A1DGAT2 | |
| SCHEMBL18249755 | 0.79 | LOXL2 (0.43) | SMN1; SMN2RAB9ANPC1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SMN1; SMN2 4828/4885RAB9A 1170/4885NPC1 33/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | SMN1; SMN2 4835/4885RAB9A 1119/4885NPC1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.